

Supporting Information (SI)

Euphorikanin A, a Diterpenoid Lactone with a Fused 5/6/7/3 Ring System from *Euphorbia kansui*

Dong-Qing Fei^{*,†}, Le-Le Dong,[†] Feng-Ming Qi,[‡] Gai-Xia Fan,[†] Hui-Hong Li,[†] Zheng-Yu Li,[†] and Zhan-Xin Zhang,^{*,†}

[†]School of Pharmacy, Lanzhou University, Lanzhou 730000, People's Republic of China

[‡]State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, People's Republic of China

* To whom correspondence should be addressed. Tel:+86-931-8915686. Fax: Tel:+86-931-8915686.

E-mail: feidq@lzu.edu.cn (D.-Q. F.); zhangzhx@lzu.edu.cn (Z.-X. Z.)

TABLE OF CONTENTS

1. Detailed experimental procedures	S3
1.1 General Experimental Procedures.....	S3
1.2 Plant Material.....	S3
1.3 Extraction and isolation.....	S3
2. NMR, HRESIMS, and IR spectra of compound 1	S4
Figure S1. ¹H NMR spectrum of euphorikanin A (1) in CDCl₃.....	S4
Figure S2. ¹³C NMR spectrum of euphorikanin A (1) in CDCl₃.....	S5
Figure S3. HSQC spectrum of euphorikanin A (1) in CDCl₃	S6
Figure S4. HMBC spectrum of euphorikanin A (1) in CDCl₃	S7
Figure S5. ¹H-¹H COSY spectrum of euphorikanin A (1) in CDCl₃.....	S8
Figure S6. NOESY spectrum of euphorikanin A (1) in CDCl₃.....	S9
Figure S7. HRESIMS spectrum of euphorikanin A (1)	S10
Figure S8. IR spectrum of euphorikanin A (1).....	S11

1. Detailed experimental procedures

1.1 General Experimental Procedures

Melting points were determined on an X-4 digital display micromelting point apparatus, and are uncorrected. Optical rotations were measured on a Perkin Elmer 341 polarimeter. IR spectra were taken on a Nicolet NEXUS 670 FT-IR spectrometer. NMR spectra were recorded on a Varian INOVA-600 NMR spectrometer with TMS as internal standard. HRESIMS data were recorded on a Thermo LTQ Orbitrap Elite mass spectrometer. Sephadex LH-20 was supplied by Amersham Pharmacia Biotech. Silica gel (200-300 mesh) used for column chromatography and silica gel GF₂₅₄ (10-40 μ M) used for TLC were supplied by the Qingdao Marine Chemical Factory, Qingdao, China. Spots were detected on TLC under UV light or by heating after spraying with 5% H₂SO₄ in C₂H₅OH (v/v).

1.2 Plant Material

The dry roots of *Euphorbia kansui* were purchased in September 2012 from Hebei Anguo Medicine Market, Anguo, China. The plant material was identified by Dr. Jian-Yin Li, School of Pharmacy, Lanzhou University, Lanzhou, China. A voucher specimen (No. 201209EK) was deposited at the School of Pharmacy, Lanzhou University.

1.3 Extraction and isolation

The dried and pulverized roots of *E. kansui* (25 kg) were extracted with 95% aqueous EtOH at room temperature four times (each time for 7 days). The solvent was evaporated under reduced pressure to yield a crude extract (470 g), which was suspended in water and then extracted with EtOAc and n-BuOH, sequentially. The EtOAc-soluble extract (324 g) was obtained after evaporation of the EtOAc solution under reduced pressure. The EtOAc extract was subjected to column chromatography over silica gel eluting with a petroleum ether-acetone step gradient system (40:1 to 1:1) to give six main fractions A-F. Fraction B (21 g) was chromatographed over silica gel column, eluted with a gradient solvent system of increasing polarity (petroleum ether-acetone, 30:1 to 4:1), yielding two subfractions B1 and B2. Subfraction B1 was subjected to repeated chromatography over silica gel (petroleum ether-EtOAc, 20:1 to 2:1) to give subfractions B1A-B1C. Subfraction B1A was purified by silica gel CC (petroleum ether-acetone, 20:1 to 2:1) followed by gel permeation chromatography (GPC) on Sephadex LH-20 in CHCl₃-MeOH (1:1) to yield an inseparable mixture. This mixture was subjected to silica gel preparative TLC using petroleum ether-acetone (5:1) to afford compound **1** (2 mg).

2. NMR, HRESIMS, and IR spectra of compound 1

Figure S1. ^1H NMR spectrum of euphorikanin A (1) in CDCl_3




Figure S2. ^{13}C NMR spectrum of euphorikanin A (**1**) in CDCl_3




Figure S3. HSQC spectrum of euphorikanin A (**1**) in CDCl₃




Figure S4. HMBC spectrum of euphorikanin A (**1**) in CDCl₃




Figure S5. ^1H - ^1H COSY spectrum of euphorikanin A (**1**) in CDCl_3




Figure S6. NOESY spectrum of euphorikanin A (**1**) in CDCl_3




Figure S7. HRESIMS spectrum of euphorikanin A (**1**)




Figure S8. IR spectrum of euphorikanin A (**1**)

